Product Description
Mechanisms of Action: Imaging Agent
Novel Mechanism: No
Modality: Diagnostic Agent
Route of Administration: Intravenous
FDA Designation: Fast Track - Priority Review - Brain Cancer *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Telix Pharm
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Australia
Active Clinical Trial Count: 2
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Brain Cancer|Glioblastoma
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
ACTRN12625000934448 |
ACTRN12625000934448 | P3 |
Not yet recruiting |
Glioblastoma|Brain Cancer |
2027-07-30 |
2025-08-31 |
Treatments |
|
NCT07100730 |
IPAX BrIGHT | P3 |
Not yet recruiting |
Glioblastoma |
2027-07-01 |
2025-08-05 |
Primary Endpoints|Treatments |
